NovaBridge Biosciences

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fu Wei

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		725,140⁽¹⁾		⁽²⁾	06/29/2036	Ordinary Shares⁽³⁾	725,140⁽¹⁾	$0	725,140⁽¹⁾	D
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		1,087,720⁽¹⁾		⁽⁴⁾	06/29/2036	Ordinary Shares⁽³⁾	1,087,720⁽¹⁾	$0	1,087,720⁽¹⁾	D
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		1,087,720⁽¹⁾		⁽⁵⁾	06/29/2036	Ordinary Shares⁽³⁾	1,087,720⁽¹⁾	$0	1,087,720⁽¹⁾	D
Restricted Share Units	⁽⁶⁾	06/29/2026		A		1,010,100⁽¹⁾		⁽⁷⁾	⁽⁷⁾	Ordinary Shares⁽³⁾	1,010,100⁽¹⁾	$0	1,010,100⁽¹⁾	D

Explanation of Responses:

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").

2. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.

3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

4. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$12.00.

5. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$16.00.

6. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

7. The RSUs vest over two years in equal annual installments on June 29, 2027 and June 29, 2028.

	/s/ Kyler Lei as attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.